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 ABSTRACT 
 
Objective: The objective of this selective EBM review is to determine whether or not 
combination nivolumab and ipilimumab is safe and effective in patients with melanoma. 
 
Study design: Review of two randomized controlled trials (RCTs) published in 2015, and one 
cohort study published in 2013.  
 
Data Sources: All of the articles were published in English language, peer reviewed journals and 
were found using PubMed and Cochrane databases.  
 
Outcomes Measured: The safety of combination nivolumab and ipilimumab was measured by 
treatment-related grade 3 or 4 adverse effects. The effectiveness was measured by progression-
free survival, which is based on disease progression and death.  
 
Results: Wolchok et al. (2013) conducted a cohort study and found that concurrent therapy with 
nivolumab and ipilimumab had a similar safety profile to previous studies with monotherapy 
(NNH = 3), and the adverse effects were generally reversible. In a randomized controlled trial, 
Larkin et al (2015) found that combination nivolumab and ipilimumab was more effective than 
nivolumab monotherapy in preventing death or disease progression (NNT = -3; p <0.01). Postow 
et al (2015) conducted a randomized controlled trial that found combination nivolumab and 
ipilimumab more effective than ipilimumab monotherapy in preventing death or disease 
progression (NNT = -3; p <0.01).  
 
Conclusions: The cohort study conducted by Wolchok et al showed that nivolumab-plus-
ipilimumab had an acceptable safety profile, as its safety was qualitatively similar to 
monotherapy and the effects were generally reversible. However, it is difficult to conclude that 
combination nivolumab and ipilimumab is safe in treatment of melanoma based on this one 
study. The two RCTs demonstrated that combining nivolumab and ipilimumab is effective at 
preventing death or disease progression of melanoma compared to using nivolumab or 
ipilimumab alone.  
 
Key Words: Nivolumab, Ipilimumab, Melanoma  
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Introduction  
 Melanoma is defined as a malignant tumor arising from melanocytes.1 Although not the 
most common type of skin cancer, it is considered the most dangerous. Clinical features of 
pigmented lesions suspicious for melanoma are an irregular notched border where the pigment 
appears to be spreading into the normal surrounding skin, as well as color variegation, 
asymmetry, diameter greater than 6mm, and any evolution in existing lesions.2 The exact cause 
of all melanomas remains unclear; however, the majority of melanomas are caused by ultraviolet 
rays.3 Ultraviolet rays damage the DNA in skin cells, which leads to mutations in certain genes, 
which ultimately leads to uncontrolled skin cell growth and division.  
Melanoma has a significant impact on the United States population. There were 
approximately 76,100 new melanoma cases diagnosed in 2014.2 Also, each year in the United 
States, an estimated 9,710 deaths are caused by melanoma.2 The annual medical costs related to 
melanoma in 2011 was $8.1 billion.4 There is no exact estimate available for the number of 
health care visits associated specifically with melanoma. However, 4.9 million people were 
treated for skin cancer in general in 2011.4  
Currently, there are several treatment options for melanoma based on the severity of the 
disease. For more localized disease, surgical excision is the treatment of choice. Sentinel lymph 
node biopsy may also be done. For metastatic melanoma, there are a number of immunotherapies 
available, such as interleukin 2, ipilimumab, nivolumab, vemurafenib, dabrafenib, and 
trametinib. Chemotherapeutic agents, such as dacarbazine, temozolomide, paclitaxel, and 
carboplatin, may also be useful in metastatic melanoma. All of the aforementioned treatment 
options are important in the treatment of melanoma. However, there are shortcomings to these 
treatment options, as evidenced by the estimated 9,710 annual deaths due to melanoma. This 
Toscano, Nivolumab/Ipilimumab in Melanoma 2 
 
paper evaluates two randomized controlled trials and one cohort study comparing the safety and 
effectiveness of combination nivolumab and ipilimumab to monotherapy nivolumab or 
monotherapy ipilimumab. 
Objective 
 The objective of this selective EBM review is to determine whether or not combination  
 
nivolumab and ipilimumab is safe and effective in patients with melanoma.  
 
Methods  
 The two randomized controlled trials and one cohort study in this review were all 
conducted with patients greater than 18 years of age diagnosed with melanoma. The intervention 
used was combination nivolumab and ipilimumab. This intervention was compared to 
monotherapy nivolumab and monotherapy ipilimumab. The outcome measured in the cohort 
study was safety, which was determined by treatment-related grade 3 or 4 adverse effects. The 
outcome measured in the two randomized controlled trials was effectiveness, which was 
determined by progression free survival based on disease progression or death.   
 To determine which articles to use in this review, keywords used were nivolumab, 
ipilimumab, and melanoma. All of the articles utilized were published in English and in peer 
reviewed journals. The articles were searched via PubMed and selected based on their relevance 
to the clinical question posed in this review and if they included patient oriented outcomes. 
Inclusion criteria included studies that were either randomized controlled trials or cohort studies. 
Exclusion criteria consisted of patients under the age of 18 years old. Statistics reported and used 
were numbers needed to treat (NNT), numbers needed to harm (NNH), and p-values.  
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Table 1: Demographics and Characteristics of included studies  
 
 
Study Type # of 
pts  
Age 
(yrs) 
Inclusion Criteria Exclusion 
Criteria 
W/D Interventions 
Wolchok, 
20135 
Cohort 86 22-89 At least 18 years old, 
diagnosis of 
measurable, 
unresectable, stage III 
or IV melanoma, 
ECOG performance 
status of 0 or 1, 
adequate organ 
function, life 
expectancy of at least 
4 months 
Active, 
untreated 
central 
nervous 
system 
metastasis, 
history of 
autoimmune 
disease, 
previous 
therapy with 
T-cell 
modulating 
antibodies, 
HIV, 
hepatitis B or 
C  
0 Escalating 
doses of IV 
nivolumab 
and 
ipilimumab 
administered 
concurrently 
every 3 weeks 
for 4 doses, 
followed by 
nivolumab 
alone every 3 
weeks for 4 
doses; 
combined 
treatment was 
subsequently 
continued 
every 12 
weeks for up 
to 8 doses  
Larkin, 
20156 
RCT 945 18-90 Histologically 
confirmed stage III or 
IV melanoma, at least 
18 years old, ECOG 
performance status of 
0 or 1, availability of 
tissue collected from 
metastatic or 
unresectable tumors, 
and known BRAF 
V600 mutation status 
ECOG 
performance 
status score 
of 2 or 
higher, active 
brain 
metastases, 
ocular 
melanoma, 
autoimmune 
disease 
0 Combination 
nivolumab 
and 
ipilimumab 
Vs. 
nivolumab 
monotherapy 
Vs. 
ipilimumab 
monotherapy 
Postow, 
20157 
RCT 142 27-87 Histologically 
confirmed stage III or 
IV melanoma, known 
BRAF V600 mutation 
status, ECOG 
performance status of 
0 or 1 
Active brain 
metastases, 
uveal 
melanoma, 
serious 
autoimmune 
disease 
0 Combination 
nivolumab 
and 
ipilimumab 
Vs. 
ipilimumab 
monotherapy 
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Outcomes Measured: The outcomes measured in this review were safety and effectiveness of 
combination nivolumab and ipilimumab. Wolchok et al, in their cohort study, determined safety 
of nivolumab-plus-ipilimumab by measuring treatment-related grade 3 or 4 adverse effects. 
Larkin et al, as well as Postow el al, determined effectiveness of nivolumab-plus-ipilimumab by 
measuring progression-free survival, which is based on disease progression and death.5,6,7  
Results  
 The two randomized controlled trials and one cohort study included in this review had 
similar inclusion and exclusion criteria, and no patients were withdrawn from the studies (Table 
1). The cohort study examined the safety of combining nivolumab and ipilimumab for use in the 
treatment of melanoma. The two randomized controlled trials compared the effectiveness of 
combining nivolumab and ipilimumab to treatment with monotherapy nivolumab or 
monotherapy ipilimumab (Table 1).  
 In the cohort study conducted by Wolchok et al, 86 total patients were included. 53 
patients were given concurrent therapy with nivolumab and ipilimumab, which meant that these 
patients were given intravenous doses of nivolumab-plus-ipilimumab every 3 weeks for 4 doses, 
followed by nivolumab alone every 3 weeks for 4 doses.5 The other 33 patients were treated with 
a sequenced regimen, which meant that these patients were previously treated with ipilimumab 
and subsequently treated with nivolumab every 2 weeks for up to 48 doses.5 Grade 3 or 4 adverse 
effects were measured in both of these groups. 53% of the concurrent-regimen group showed 
grade 3 or 4 adverse effects and 18% of the sequenced-regimen group showed grade 3 or 4 
adverse effects (Table 2).5 The NNH for the concurrent-regimen group was measured to be 3, 
with a relative risk increase of 1.94 and an absolute risk increase of 35 (Table 2).    
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Table 2: Concurrent-regimen of nivolumab-plus-ipilimumab vs. sequenced-regimen of 
nivolumab-plus-ipilimumab comparison of grade 3 or 4 adverse effects (Wolchok et al, 2013)5 
Treatment-related grade 3 or 4 
adverse effects  
Relative risk 
increase (RRI) 
Absolute risk 
increase 
(ARI) 
Number needed 
to harm (NNH) 
Sequenced-
regimen 
(CER) 
Concurrent-
regimen (EER) 
EER- CER 
CER 
EER - CER 1/ARI 
       18%          53% 1.94 0.35 3 
 
  
Larkin et al conducted a randomized controlled trial comparing the effectiveness of 
nivolumab-plus-ipilimumab to nivolumab alone. To measure the effectiveness, the authors used 
progression-free survival by examining disease progression or death. Of the 314 patients in the 
nivolumab-plus-ipilimumab group, 23.6% had disease progression or death, and of the 316 
patients in the nivolumab monotherapy group, 50.8% had disease progression or death (p <0.01). 
Compared to the nivolumab monotherapy group, the nivolumab-plus-ipilimumab experimental 
group was found to have a NNT = -3, showing that for every 3 patients treated with nivolumab-
plus-ipilimumab, 1 fewer patient had disease progression or death compared to nivolumab alone. 
(Table 3).  
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Table 3: nivolumab-plus-ipilimumab vs. nivolumab monotherapy comparison of disease 
progression or death 
Disease progression or death Relative benefit 
increase (RBI) 
Absolute 
benefit 
increase 
(ABI) 
Number needed 
to treat (NNT) 
nivolumab 
alone (CER) 
nivolumab-plus-
ipilimumab (EER) 
EER- CER 
CER 
EER - CER 1/ARI 
       50.8%          23.6% -0.535 -0.272 -3 
 
 Postow et al conducted a randomized controlled trial comparing the effectiveness of 
nivolumab-plus-ipilimumab to ipilimumab alone. As Larkin et al did, Postow et al. measured 
effectiveness by examining disease progression and death. Of the 72 patients treated with 
nivolumab-plus-ipilimumab, 30 patients had disease progression or death, and of 37 patients 
treated with ipilimumab alone, 25 patients had disease progression or death (p <0.01).7 When 
comparing the nivolumab-plus-ipilimumab group to the ipilimumab monotherapy group, the 
nivolumab-plus-ipilimumab group was found to have a NNT = -3, suggesting that for every 3 
patients treated with nivolumab-plus-ipilimumab, 1 fewer patient had disease progression or 
death compared to ipilimumab alone (Table 4).  
Table 4: nivolumab-plus-ipilimumab vs. ipilimumab monotherapy comparison of disease 
progression or death 
Disease progression or death Relative benefit 
increase (RBI) 
Absolute 
benefit 
increase 
(ABI) 
Number needed 
to treat (NNT) 
ipilimumab 
alone (CER) 
nivolumab-plus-
ipilimumab (EER) 
EER- CER 
CER 
EER - CER 1/ARI 
       68%          42% -0.62 -0.26 -3 
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Discussion  
 The studies presented in this review examined the safety and effectiveness of nivolumab-
plus-ipilimumab. Although these drugs in combination proved effective, a major obstacle is the 
price of these drugs. These drugs are available in the United States, but to treat a typical patient 
with combination nivolumab and ipilimumab, it is estimated to cost $295,566.8 Even with some 
insurance coverage, these drugs may prove to be too expensive for many melanoma patients to 
afford. Another problem with this combination treatment may be some fatal adverse effects. 
Although Wolchok et al. concluded in their cohort study that nivolumab-plus-ipilimumab had an 
appropriate safety profile with no reported adverse effect related deaths, nivolumab has been 
observed in the past to be associated, although rare, with fatal toxic epidermal necrolysis and 
adrenal insufficiency.9 Despite these rare adverse effects, there are no contraindications listed for 
the use of nivolumab or ipilimumab.9 Though ipilimumab has only been used in melanoma thus 
far, nivolumab has been studied and used for other cancers as well, such as lung and renal 
cell.9,10  
 Although the studies used in this review had very high validity, it may have been 
beneficial if this review itself could have included more than two randomized controlled trials. 
There also seemed to be a relatively large difference in the sample sizes used in the randomized 
controlled trials, as the Larkin et al study included 945 patients, whereas the Postow et al study 
only included 142 patients. Despite the difference in sample size, both studies were double blind, 
randomized controlled trials that proved to be valid.   
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Conclusion  
 After examination of the three studies included in this review, it is difficult to conclude 
that combination nivolumab and ipilimumab is safe in patients with melanoma, as only one study 
focused on the safety of the regimen. However, it does appear that combination nivolumab and 
ipilimumab is effective in patients with melanoma. Combination nivolumab-plus-ipilimumab 
yielded lower disease progression and death compared to either nivolumab or ipilimumab alone. 
The only flaw to really consider with these studies is the smaller sample size in the Postow et al 
study. Since nivolumab is currently being used and studied in other cancers, further research into 
the addition of ipilimumab in these cancers may be warranted, as ipilimumab has only been used 
in melanoma treatment to this point and seems to be effective when combined with nivolumab.
 References 
 
1. Menzies AM, Saw RPM, Fernandez-Penas P. Melanoma. Epocrates. 
http://online.epocrates.com.ezproxy.pcom.edu:2048/diseases/26821/melanoma/definition. 
Published January 18, 2016. Accessed October 9, 2016.  
2. Papadakis MA, McPhee SJ. Current Medical Diagnosis and Treatment 2016. 55th ed. 
New York, New York: McGraw-Hill Education; 2016.  
3. What causes melanoma skin cancer. American Cancer Society. 
http://www.cancer.org/cancer/skincancer-melanoma/detailedguide/melanoma-skin-
cancer-what-causes. Published May 20, 2016. Accessed October 9, 2016. 
4. Firger J. Skin Cancer Costs Rising Rapidly in U.S. CBS News. 
http://www.cbsnews.com/news/melanoma-skin-cancer-costs-rising-rapidly-in-us/. 
Published November 10, 2014. Accessed October 9, 2016.   
5. Wolchok JD, Kluger H, Callahan MK, et al. Nivolumab plus ipilimumab in advanced 
melanoma. N Engl J Med. 2013;369(2):122-133  
6. Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or 
monotherapy in untreated melanoma. N Engl J Med. 2015;373(1):23-34 
7. Postow MA, Chesney J, Pavlick AC, et al. Nivolumab and ipilimumab versus ipilimumab 
in untreated melanoma. N Engl J Med. 2015;372(21):2006-2017. 
8. Andrews A. Treating with Checkpoint Inhibitors—Figure $1 Million per Patient. 
American Health and Drug Benefits. 2015;8. 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4570079/.  
9. Nivolumab. Up To Date. https://www-uptodate-
com.ezproxy.pcom.edu/contents/nivolumab-drug-
information?source=search_result&search=nivolumab&selectedTitle=1~51. Published 
2016. Accessed November 27, 2016.  
10. Ipilimumab. Up To Date. https://www-uptodate-
com.ezproxy.pcom.edu/contents/ipilimumab-drug-
information?source=preview&search=ipilimumab&anchor=F16322871#F16322871 . 
Published 2016. Accessed November 27, 2016.  
 
 
 
 
 
   
 
